Dactinomycin
Also known as: ACT-D, Actinomycin D, Cosmegen, DACT, Dactinomycin, Lyovac-Cosmegen
Source Dactinomycin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dactinomycin (also known as actinomycin D) is an intravenous, prescription‑only chemotherapeutic antibiotic belonging to the actinomycin/chromopeptide family. It is approved for use in cancer treatment, most notably as a component of the VAC (vincristine, dactinomycin, cyclophosphamide) regimen for intermediate‑risk rhabdomyosarcoma in children. The drug is administered by infusion and has been studied in numerous oncology trials and reviews.
Mechanism of Action
Intercalates into double-stranded DNA by inserting between adjacent guanine-cytosine base pairs, inhibiting DNA-dependent RNA polymerase and thereby blocking transcription. Also causes single- and double-strand DNA breaks at high concentrations.
What the Research Shows
Clinical evidence for dactinomycin comes largely from its role in combination chemotherapy. A Children’s Oncology Group trial (COG D9803) compared standard VAC therapy with VAC alternating with topotecan; the VAC arm, which includes dactinomycin, achieved a 4‑year failure‑free survival of 73% in 264 patients, a result not significantly improved by the alternating regimen. A broader oncology review notes that dactinomycin, along with many other agents, can disrupt the ovarian microenvironment, leading to follicle loss and premature ovarian insufficiency. Additionally, a 1992 oncology overview reported that dactinomycin has produced at least isolated instances of hypersensitivity reactions, although such events appear rare compared with other chemotherapeutics.
Reported Benefits
Evidence from the COG D9803 trial demonstrates that dactinomycin, as part of the VAC regimen, contributes to a high rate of disease control in intermediate‑risk rhabdomyosarcoma, with a 73% four‑year failure‑free survival. Its inclusion in standard pediatric sarcoma protocols reflects its established antitumor activity within combination regimens.
Limitations of the Evidence
The literature provides limited data on dactinomycin as a single agent; most findings are from combination therapies. Reports of hypersensitivity reactions are rare but documented, and the drug may contribute to chemotherapy‑associated ovarian damage through microenvironment disruption. Comparative studies have not shown superiority over alternative regimens, and long‑term safety data beyond specific pediatric cancers remain sparse.
Safety Considerations
Dactinomycin has been associated with isolated hypersensitivity reactions, which can be of the IgE‑mediated or non‑specific type. In women of reproductive age, the drug may affect the ovarian microenvironment, potentially leading to reduced fertility or early menopause. Overall safety profiles are derived from combination therapy studies; clinicians monitor for typical chemotherapy toxicities and adjust treatment as needed.
How It Is Administered
Dactinomycin is administered intravenously, typically as an infusion over a prescribed period. Formulations are supplied for parenteral use only; dosing schedules vary according to the specific chemotherapy protocol.
Routes of Administration
Goals & Uses
- Gestational trophoblastic diseaseOncologyHigh
- RhabdomyosarcomaOncologyHigh
- Wilms tumourOncologyHigh
- Wilms tumor treatmentOncologyHigh
- Gestational trophoblastic neoplasiaOncologyHigh
- Ewing sarcomaOncologyHigh
- Rhabdomyosarcoma treatmentOncologyHigh
- Testicular carcinoma treatmentOncologyModerate
- Ewing sarcoma treatmentOncologyHigh
- Regional perfusion for solid tumorsOncologyModerate
Contraindications
- Known hypersensitivity to actinomycin DAllergyHigh
- Chickenpox (varicella) or herpes zoster infectionInfectionHigh
- Severe hepatic impairmentOrganModerateLiver function concerns
- Severe bone‑marrow suppressionHematologicHigh
- Recent live vaccinesImmunologicalModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Severe bone marrow suppressionHematologicHigh
- Hepatic veno-occlusive disease (in combination with radiation)HepatotoxicityHigh
Adverse Effects
- HepatotoxicityHepaticUncommonLiver injury or dysfunction
- AlopeciaDermatologicCommonHair loss
- Mucositis / stomatitisGastrointestinalCommon
- Nausea and vomitingGastrointestinalCommon
- MucositisGastrointestinal / MucosalCommon
- Tissue necrosis (extravasation)Local/dermatologicalUncommon
- MyelosuppressionHematologicCommon
- Hepatotoxicity / veno-occlusive diseaseHepaticUncommon
Drug Interactions
- Live vaccinesHigh
- Radiation therapyHigh
- CYP3A4 inhibitors (e.g., ketoconazole)Low
- Other myelosuppressive agents (e.g., anthracyclines, cyclophosphamide)High
- Other myelosuppressive agentsModerate
- Vitamin K antagonists (warfarin)Moderate
Population Constraints
- Infants < 6 monthsPediatricRelative
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveAbsolute
- ElderlyAgeRelative
- Patients with hepatic impairmentOrgan FunctionRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionApprovedApproved: Wilms tumour, Rhabdomyosarcoma, Ewing sarcoma, Gestational trophoblastic disease
- United StatesApprovedApproved: Wilms tumour, Rhabdomyosarcoma, Ewing sarcoma, Gestational trophoblastic diseasePrescribed under oncologist supervision; IV infusion
- United KingdomApprovedApproved: Wilms tumour, Rhabdomyosarcoma, Ewing sarcoma, Gestational trophoblastic disease
Approved in the US, EU and UK for Wilms tumour, rhabdomyosarcoma, Ewing sarcoma and gestational trophoblastic disease; administered under oncology specialist supervision.
Evidence & Sources
- Journal ArticleModerateWeiss RB1992-01-01T00:00:00.000000Z
- Journal ArticleModerateGuo Y, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateArndt CA, et al.2009-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of cancer is dactinomycin most commonly used to treat?
It is most frequently used as part of the VAC regimen for intermediate‑risk rhabdomyosarcoma in children, where it contributes to disease control and long‑term survival.
Can dactinomycin cause allergic reactions?
Yes, isolated hypersensitivity reactions have been reported, ranging from IgE‑mediated to non‑specific mast cell activation, although such events are uncommon.
Does dactinomycin affect fertility?
Reviews indicate that dactinomycin, like many chemotherapeutics, can disrupt the ovarian microenvironment, potentially leading to reduced ovarian reserve and early menopause in premenopausal women.
How is dactinomycin given to patients?
The drug is delivered by intravenous infusion, incorporated into multi‑drug chemotherapy protocols; exact infusion rates and schedules depend on the treatment regimen.
Is dactinomycin more effective than other regimens for rhabdomyosarcoma?
A large randomized trial showed that the standard VAC regimen (including dactinomycin) performed similarly to an alternating VAC/topotecan schedule, with no significant improvement in failure‑free survival for the alternative.
What is Dactinomycin?
Dactinomycin (also known as actinomycin D) is an intravenous, prescription‑only chemotherapeutic antibiotic belonging to the actinomycin/chromopeptide family. It is approved for use in cancer treatment, most notably as a component of the VAC (vincristine, dactinomycin, cyclophosphamide) regimen for intermediate‑risk rhabdomyosarcoma in children. The drug is administered by infusion and has been studied in numerous oncology trials and reviews.
What is Dactinomycin used for?
Dactinomycin is educationally associated with: Gestational trophoblastic disease, Rhabdomyosarcoma, Wilms tumour, Wilms tumor treatment, Gestational trophoblastic neoplasia, Ewing sarcoma, Rhabdomyosarcoma treatment, Testicular carcinoma treatment, Ewing sarcoma treatment, Regional perfusion for solid tumors. Educational only — not medical advice.
How is Dactinomycin administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Dactinomycin?
Reported adverse effects include: Hepatotoxicity, Alopecia, Mucositis / stomatitis, Nausea and vomiting, Mucositis, Tissue necrosis (extravasation), Myelosuppression, Hepatotoxicity / veno-occlusive disease. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dactinomycin?
Recorded contraindications: Known hypersensitivity to actinomycin D, Chickenpox (varicella) or herpes zoster infection, Severe hepatic impairment, Severe bone‑marrow suppression, Recent live vaccines, Pregnancy, Severe bone marrow suppression, Hepatic veno-occlusive disease (in combination with radiation). Consult a qualified clinician before use.